Phase II study of hyper-CVAD [intensive chemotherapy] and alemtuzumab (Campath) in aggressive CD52+ lymphoprofierative disorders
Phase of Trial: Phase II
Latest Information Update: 21 Dec 2005
At a glance
- Drugs Alemtuzumab (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Vincristine
- Indications Lymphoproliferative disorders
- Focus Therapeutic Use
- 21 Dec 2005 New trial record.